---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-051035"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:21:33.923214+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M

## Summary
- Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
- Combination reduced waist circumference by 3.2 cm (1.25 inches) vs semaglutide alone.
- Rebound weight gain was 18.1% vs 49.8% for semaglutide alone over 12 weeks post-treatment.
- Q3 2025 net loss of $12.8M; cash $35.3M; runway into 2027.
- Extension study fully enrolled (43 patients); data expected Q1 2026.

## SEC filing metadata
- accession: 0001628280-25-051035
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/0001628280-25-051035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/skye-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-051035
- JSON: https://secwatch.observer/filing/0001628280-25-051035.json
- Plain text: https://secwatch.observer/filing/0001628280-25-051035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.